Fundacion Ars Medica | San Salvador de Jujuy, Argentina

Research site

(Unclaimed)

Location

Coronel Puch 497, San Salvador de Jujuy, Jujuy, Argentina

Site insights

Top conditions

Top treatments

Pembrolizumab

LY3009806

Ramucirumab

Bintrafusp Alfa

M7824

Nivolumab

Gemcitabine

Bemarituzumab

LY2801653

Cisplatin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 7 total trials

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum d...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously tre...

Active, not recruiting

Metastatic Breast Cancer

Drug: Abemaciclib

Drug: Prophylactic Loperamide

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in parti...

Active, not recruiting

Advanced Cancer

Metastatic Cancer

Drug: Ramucirumab

Drug: Gemcitabine

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Drug: ABP 234

Drug: Pembrolizumab (EU)

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab